The Moat Isn't a Dashboard
Most longevity protocols have a longevity problem: an over-optimized check-up, a fancy bio age algorithm, but little-to-no guidance for the 360 days after.
That's why the moat isn't a dashboard. The moat is a clinically-safe prevention loop that turns results into durable behavior change, at scale.
Clinically-safe
- Advice is bounded by medical governance, not vibes or trends.
- Clear escalation rules: self-manage vs when to see a clinician, urgently or not.
- Contraindications are explicit (meds, conditions, pregnancy, injury, eating disorders, etc.).
- Uncertainty is communicated (confidence, "watchful waiting", when to re-test).
- Documentation exists: what was recommended, why, and on what evidence tier.
Prevention loop
Not "test → plan → goodbye", but a repeatable cadence: Detect → Decide → Do → Verify → Re-plan.
- Detect: measurement + interpretation that reduces ambiguity.
- Decide: triage into lanes (clinical follow-up / risk reduction / optimization) with different cadence.
- Do: staged actions that survive real life (defaults, scheduling, friction removal).
- Verify: leading indicators in weeks, not only biomarkers in a year.
- Re-plan: adjust every 4–8 weeks based on adherence and response.
Durable behavior change
- The target isn't "motivation". The target is repeatability under stress, travel, and busy weeks.
- Plans are small: 1–3 actions max per "sprint"; progression only after stability.
- Relapse is designed: restart flows, smaller goals, no shame mechanics.
- Identity + environment win: routines, cues, and constraints beat information.
- Progress is measured and celebrated: small wins made visible, meaningful, and cumulative (not gimmicky streaks).
- Success is measured as adherence + recovery after lapses, not app opens.
At scale
- Works for thousands without becoming unsafe or purely human-driven.
- Automation handles the common path; humans oversee triage and exceptions.
- Personalization is systematic: rules + risk lanes + preference capture, not bespoke hand-holding.
- Commercial durability: priced to cost-to-serve (clinical time, support, platforms stack costs) with bounded variable costs and clear escalation criteria.
- Renewal economics: the loop creates legible value between (bi/)annual tests, increasing renewal and amortizing CAC.
- The operating system is cross-functional: medical, engineering, and commercial teams share the same definitions of "safe", "working", and "done".
Diagnostics can be purchased. Dashboards can be copied. A prevention loop that is medically safe, behaviorally effective, and operationally/commercially scalable is the hard part.
I know that YDUN, ARO, Aeon are working on the hard part. Who else is?
← Back to all posts